| Aug 7 |
Sarepta Therapeutics, Inc. (SRPT) Q2 2024 Earnings Call Transcript
|
| Aug 7 |
Compared to Estimates, Sarepta Therapeutics (SRPT) Q2 Earnings: A Look at Key Metrics
|
| Aug 7 |
Sarepta Therapeutics falls on revenue miss, weak outlook
|
| Aug 7 |
Sarepta Therapeutics: Q2 Earnings Snapshot
|
| Aug 7 |
Sarepta Therapeutics Non-GAAP EPS of $0.44 misses by $0.03, revenue of $362.9M misses by $24.91M
|
| Aug 7 |
Sarepta Therapeutics Announces Second Quarter 2024 Financial Results and Recent Corporate Developments
|
| Aug 6 |
Sarepta Therapeutics Q2 2024 Earnings Preview
|
| Aug 5 |
What Makes Sarepta Therapeutics (SRPT) a New Buy Stock
|
| Aug 1 |
Sarepta Therapeutics (NASDAQ:SRPT) A Bull Case Theory
|
| Jul 31 |
Sanofi unit Genzyme sues Sarepta alleging patent infringement in Duchenne drug
|
